The aim of this study was to investigate predictors of progression in patients with asymptomatic IgM monoclonal gammopathies observed over a long period, incorporating immunoparesis, BM infiltration, and the presence of MYD88 L265P mutation with an intention to find an accessible and reproducible risk model overtaking the definition gap and highlighting a population of patients that may be categorized as IgM MGUS or SWM. This evidence concerns the gene CD40LG and monoclonal gammopathy.